- Trials with a EudraCT protocol (44,393)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
44,393 result(s) found.
Displaying page 11 of 2,220.
| EudraCT Number: 2019-000902-31 | Sponsor Protocol Number: ECACOR19 | Start Date*: 2019-09-05 |
| Sponsor Name:OMEQUI | ||
| Full Title: Healing efficacy after impacted mandibular third molar surgery with the use of autologous platelet-rich fibrin: a randomized controlled clinical study | ||
| Medical condition: If the addition of L-PRF reduces postoperative pain and inflammation, as well as complications, after extraction of lower third molars | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2016-000866-44 | Sponsor Protocol Number: NC-6004-008 | Start Date*: 2017-01-17 | |||||||||||
| Sponsor Name:NanoCarrier Co, Ltd | |||||||||||||
| Full Title: Phase I/II Clinical Trial of NC-6004 in Combination with 5-FU and Cetuximab as First-line Treatment in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of The Head and Neck | |||||||||||||
| Medical condition: Metastatic squamous cell carcinoma of the head and neck | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) BG (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-000608-13 | Sponsor Protocol Number: MK-4117-201 | Start Date*: 2017-02-09 | |||||||||||
| Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
| Full Title: A phase III multicentre, parallel-group, randomized, placebo-controlled, double-blind clinical trial to study the efficacy and safety of MK-4117 in Japanese subjects with chronic urticaria. | |||||||||||||
| Medical condition: Chronic urticaria (a skin condition caused by an allergy) | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-001365-92 | Sponsor Protocol Number: 1 | Start Date*: 2016-10-10 | |||||||||||
| Sponsor Name:Center for Diabetes Research, Gentofte Hospital | |||||||||||||
| Full Title: Meal-time Administration of exenatide for Glycaemic control in type 1 diabetic Cases: A randomised, placebo-controlled trial | |||||||||||||
| Medical condition: Type 1 Diabetes | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-002852-26 | Sponsor Protocol Number: MS200588-0004 | Start Date*: 2016-12-07 | |||||||||||
| Sponsor Name:Merck KGaA | |||||||||||||
| Full Title: A multicenter, randomized, double-blind, Phase III trial to evaluate the safety, immunogenicity, and efficacy of MSB11022 compared with Humira® in patients with moderately to severely active rheuma... | |||||||||||||
| Medical condition: moderately to severely active rheumatoid arthritis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) GB (Completed) HU (Completed) DE (Completed) LT (Prematurely Ended) BG (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-002862-30 | Sponsor Protocol Number: B7981006 | Start Date*: 2017-01-31 | |||||||||||
| Sponsor Name:Pfizer Inc 235 East 42nd Street, New York, NY10017 US | |||||||||||||
| Full Title: A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO ASSESS THE EFFICACY AND SAFETY PROFILE OF PF-06651600 IN SUBJECTS WITH MODERATE TO SEVERE ACTIVE R... | |||||||||||||
| Medical condition: RHEUMATOID ARTHRITIS | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) CZ (Completed) SK (Completed) BG (Completed) DE (Completed) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-005004-26 | Sponsor Protocol Number: ARC010 | Start Date*: 2017-04-12 |
| Sponsor Name:Aimmune Therapeutics, Inc. | ||
| Full Title: AR101 TRIAL IN EUROPE MEASURING ORAL IMMUNOTHERAPY SUCCESS IN PEANUT ALLERGIC CHILDREN (ARTEMIS) | ||
| Medical condition: Peanut Allergy | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: GB (Completed) FR (Completed) DE (Completed) ES (Completed) SE (Completed) IE (Completed) IT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2017-000188-33 | Sponsor Protocol Number: MK-8616-146 | Start Date*: 2017-10-27 | |||||||||||
| Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
| Full Title: A Phase 4 Randomized, Active-Comparator Controlled Trial to Study the Efficacy and Safety of Sugammadex (MK-8616) for the Reversal of Neuromuscular Blockade Induced by Either Rocuronium Bromide or ... | |||||||||||||
| Medical condition: Reversal of neuromuscular blockade | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) BE (Completed) AT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-002052-27 | Sponsor Protocol Number: DRM04-HH04 | Start Date*: 2015-10-14 | |||||||||||
| Sponsor Name:Dermira, Inc. | |||||||||||||
| Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED EFFICACY AND SAFETY STUDY OF DRM04 IN SUBJECTS WITH AXILLARY HYPERHIDROSIS | |||||||||||||
| Medical condition: Primary axillary hyperhidrosis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-002164-16 | Sponsor Protocol Number: CPH-301-201030 | Start Date*: 2016-04-11 | |||||||||||
| Sponsor Name:CROMA-PHARMA GmbH | |||||||||||||
| Full Title: Randomized double blind Phase 3 study to assess the efficacy and safety of BoNT/A-DP in the treatment of glabellar lines in comparison with placebo followed by an open label extension study | |||||||||||||
| Medical condition: Moderate to severe glabellar lines | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) PL (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-004336-35 | Sponsor Protocol Number: IDN-6556-12 | Start Date*: 2016-05-20 | |||||||||||
| Sponsor Name:Conatus Pharmaceuticals Inc. | |||||||||||||
| Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan (IDN-6556), an Oral Caspase Inhibitor, in Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis | |||||||||||||
| Medical condition: | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-000371-24 | Sponsor Protocol Number: DOBO-01-16 | Start Date*: 2016-05-24 |
| Sponsor Name:Laboratorios Ordesa | ||
| Full Title: Multicenter pilot study for comparison of the efficacy of vaginal capsules with boric acid and L. gasseri and L. rhamnosus versus other vaginal drugs, in patients with bacterial or candida Vulvovag... | ||
| Medical condition: Bacterial or candidiasic vulvovaginitis | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2015-002145-63 | Sponsor Protocol Number: INMiND-02 | Start Date*: 2015-10-15 | |||||||||||
| Sponsor Name:University of Southampton | |||||||||||||
| Full Title: A double-blind, placebo-controlled study of the effect of a TNF alpha inhibitor, etanercept (Enbrel), on microglial activation in amyloid PET positive patients with Mild Cognitive Impairment due to... | |||||||||||||
| Medical condition: Mild Cognitive impairment- due to Alzheimer's disease- intermediate likelihood | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-005051-28 | Sponsor Protocol Number: 20140336 | Start Date*: 2016-08-22 | |||||||||||
| Sponsor Name:Amgen Inc | |||||||||||||
| Full Title: An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Etelcalcetide (AMG 416) in Paediatric Subjects Aged 2 to less than 18 Years with Sec... | |||||||||||||
| Medical condition: Secondary Hyperparathyroidism (sHPT) Receiving Maintenance Haemodialysis | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) BE (Completed) LT (Completed) GB (Completed) PL (Completed) Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-002069-77 | Sponsor Protocol Number: RG101-05 | Start Date*: 2016-12-01 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Regulus Therapeutics Inc. | ||||||||||||||||||||||||||||||||||||||
| Full Title: An Observational Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Have Previously Received RG-101 | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Hepatitis C Patients | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: GR (Completed) HU (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2016-004728-48 | Sponsor Protocol Number: MK-1439-043 | Start Date*: 2016-11-23 | |||||||||||
| Sponsor Name:Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc. | |||||||||||||
| Full Title: A Study to Evaluate the Comparative Bioavailability of the Investigational Oral Pediatric Minitablet Formulation of MK-1439 Compared to the Adult Formulation of MK-1439 in Healthy Adult Subjects | |||||||||||||
| Medical condition: HIV – Human Immunodeficiency Virus | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-000994-35 | Sponsor Protocol Number: 06032017 | Start Date*: 2018-08-02 | |||||||||||
| Sponsor Name:Hospital General Universitario de Alicante | |||||||||||||
| Full Title: Study of tolerability of iron liposome compared to ferrous sulphate in pregnant women with iron deficiency anemia. | |||||||||||||
| Medical condition: Iron deficiency anaemia | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-005510-34 | Sponsor Protocol Number: MMV_DSM265_14_01 | Start Date*: 2015-09-30 | |||||||||||
| Sponsor Name:Medicines for Malaria Venture | |||||||||||||
| Full Title: Evaluation of the prophylactic antimalarial activity of a single dose of DSM265 in non-immune healthy adult volunteers by controlled human malaria infection with PfSPZ Challenge | |||||||||||||
| Medical condition: Healthy volunteers; controlled human malaria infection with PfSPZ | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-000727-25 | Sponsor Protocol Number: 47582 | Start Date*: 2017-03-28 |
| Sponsor Name:Isala Klinieken | ||
| Full Title: The effect of ARTISS on latissimus dorsi donor site seroma formation after breast reconstruction: a randomised controlled trial. | ||
| Medical condition: The aim of this study is to investigate the effect of the fibrin sealant ARTISS compared with our standard care on total volume of donor site seroma after harvesting a LD in immediate breast recons... | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2015-002955-85 | Sponsor Protocol Number: AVICCI001 | Start Date*: 2016-01-21 | |||||||||||
| Sponsor Name:Imperial College London | |||||||||||||
| Full Title: A feasibility study to assess the effects of AntiretroViral Intensification with Cenicriviroc for the management of HIV-associated Cognitive Impairment. The AVICCI study | |||||||||||||
| Medical condition: Human Immunodeficiency Virus | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.